Get the Stockscreener App
5.80
0.00%
0.00
After Hours:
5.77
-0.03
-0.52%
Bolt Biotherapeutics Inc stock is traded at $5.80, with a volume of 14,332.
It is up +0.00% in the last 24 hours and up +12.00% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$5.80
Open:
$5.83
24h Volume:
14,332
Relative Volume:
0.65
Market Cap:
$11.13M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-3.1694
EPS:
-1.83
Net Cash Flow:
$-69.73M
1W Performance:
+10.27%
1M Performance:
+12.00%
6M Performance:
-10.41%
1Y Performance:
-54.90%
1-Day Range:
$5.745
$5.95
1-Week Range:
$5.40
$6.625
52-Week Range:
$4.59
$14.36
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
5.80 | 11.13M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Earnings visualization tools for Bolt Biotherapeutics Inc.Weekly Profit Report & Daily Growth Stock Investment Tips - newser.com
Published on: 2025-10-13 09:15:08 - newser.com
Will Bolt Biotherapeutics Inc. (6LP0) stock issue positive guidance2025 Price Action Summary & AI Driven Price Forecasts - newser.com
Is Bolt Biotherapeutics Inc. reversing from oversold territoryQuarterly Trade Summary & Consistent Profit Trading Strategies - newser.com
Will Bolt Biotherapeutics Inc. stock maintain momentum in 20252025 Earnings Surprises & Entry Point Strategy Guides - newser.com
Can Bolt Biotherapeutics Inc. (6LP0) stock test all time highsWeekly Gains Summary & Verified Technical Signals - newser.com
Candlestick signals on Bolt Biotherapeutics Inc. stock todayRisk Management & Consistent Profit Alerts - newser.com
Regression analysis insights on Bolt Biotherapeutics Inc. performanceTrade Volume Report & Short-Term Trading Opportunity Alerts - newser.com
Bolt Biotherapeutics Inc. stock daily chart insightsTake Profit & Long-Term Capital Growth Strategies - newser.com
Bolt Biotherapeutics Inc Stock Analysis and ForecastMarket Liquidity Analysis & Small Budget Trading Portfolio - earlytimes.in
Reversal indicators forming on Bolt Biotherapeutics Inc. stockTrade Analysis Summary & Weekly Market Pulse Updates - newser.com
How Bolt Biotherapeutics Inc. stock reacts to inflationary pressures2025 Risk Factors & Trade Opportunity Analysis Reports - newser.com
Historical volatility pattern of Bolt Biotherapeutics Inc. visualized2025 Institutional Moves & Fast Exit Strategy with Risk Control - newser.com
What analysts say about Bolt Biotherapeutics Inc stockTrading Volume Trends & Free Tap Rapid Wealth - earlytimes.in
How Bolt Biotherapeutics Inc. (6LP0) stock correlates with oil marketsQuarterly Earnings Summary & Fast Gain Stock Trading Tips - newser.com
Will Bolt Biotherapeutics Inc. (6LP0) stock benefit from Fed rate cutsJuly 2025 Market Mood & Daily Oversold Stock Bounce Ideas - newser.com
Tools to monitor Bolt Biotherapeutics Inc. recovery probability2025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Real time breakdown of Bolt Biotherapeutics Inc. stock performanceQuarterly Trade Report & Daily Oversold Stock Bounce Ideas - newser.com
Will Bolt Biotherapeutics Inc. stock split attract more investors2025 Top Decliners & Intraday High Probability Alerts - newser.com
Is Bolt Biotherapeutics Inc. stock overvalued by current metricsWeekly Market Report & Technical Pattern Based Signals - newser.com
Applying sector rotation models to Bolt Biotherapeutics Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Published on: 2025-10-05 02:47:09 - newser.com
Finance Watch: Job Cuts At Takeda, Bolt, Innate, X4 As Strategies Shift - insights.citeline.com
Layoff Tracker: CSL Vifor, Bolt Cut Staff - BioSpace
Custom watchlist performance reports with Bolt Biotherapeutics Inc.Recession Risk & AI Based Buy and Sell Signals - newser.com
Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Morning Market Movers: ASBP, FICO, ESLA See Big Swings - RTTNews
Morning Market Movers: CIGL, UFG, FRMI, KDK See Big Swings - RTTNews
AMD, Occidental Petroleum, Bolt Biotherapeutics - TradingView
Bolt Biotherapeutics dips after cancer therapy trial delay - TradingView
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - Benzinga
BOLT Updates Phase 1 Study Protocol for BDC-4182 with Strategic Adjustments - GuruFocus
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - GlobeNewswire
Bolt Biotherapeutics to Cut Workforce by 50%; Cancer Drug Trial Data Expected in Q3 of 2026 - MarketScreener
Bolt Biotherapeutics delays clinical data, cuts workforce by half - Investing.com Canada
Bolt Biotherapeutics stock falls after clinical data delay to 2026 By Investing.com - Investing.com Canada
Major 50% Workforce Cut: Bolt Bio Extends Cash Runway to 2027, Delays Key Cancer Drug Trial Results - Stock Titan
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bolt Biotherapeutics Inc Stock (BOLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Quinn William P. | President, CEO and CFO |
Dec 16 '24 |
Buy |
0.50 |
2,500 |
1,241 |
41,272 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):